Blood Cancer | J&J withMe

J&J withMe in your country

Haematology

Haematology is the study of blood, blood diseases, and blood-forming tissues and organs. Haematologists focus on the diagnosis, treatment and prevention of blood-related disorders and malignancies. They also focus on diseases of the bone marrow and lymphatic organs such as the lymph node, thymus, spleen, and tonsils which are fed by blood cells and are crucial for the body’s immune response.

Building on a three-decade legacy in oncology and nearly 20 years of dedicated leadership, Johnson & Johnson’s commitment to pioneer new therapeutic advances and continue redefining treatment paradigms has never been stronger.

We are focused in areas of highest unmet need where we believe we can disrupt and truly transform cancer care. This includes multiple myeloma, B-cell malignancies, lung cancer, prostate cancer, and other areas within genitourinary oncology.

Johnson & Johnson Innovative Medicine and Haematology

At Johnson & Johnson Innovative Medicine, strong collaborations are essential to pioneering innovative solutions in the field of haematology and change the way blood-related conditions are diagnosed and treated. We work side-by-side with specialists, researchers and patient advocacy groups across Europe to deliver the best possible outcome by providing a platform for knowledge exchange and innovation.

In 2019, we introduced the Haematology Outcomes Network in Europe (HONEUR), a collaborative network that partners with data centres across Europe. HONEUR enables us to share real-world data to further develop our knowledge of blood malignancies and offer patients the most suitable treatment possible. At Johnson & Johnson, we believe that real-world data has the transformational potential to help us develop new tools and evidence-based therapies and evolve from disease-centred to patient-centred models of healthcare.

Patients’ health experiences and needs inform and inspire everything we do and guide our way forward in developing equitable approaches and breakthroughs that help us get in front of cancer. We don’t just want to offer solutions. We also want to improve the visibility of blood-related conditions and achieve better outcomes by working together with people and organisations close to patients and their loved ones. By increasing awareness and understanding of those affected by hematologic malignancies, we can enhance support for them and further drive drug development and breakthrough medical therapies and technologies.

Explore our Disease Areas

Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia is a rare, fast-acting form of blood cancer that develops in the bone marrow and affects immature white blood cells that would usually grow into various healthy blood cells. In AML, these abnormal blood cells do not mature and instead replicate and replace healthy cells, keeping important organs from functioning, thereby weakening the immune and healing processes.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia is a slow-growing cancer of the blood and bone marrow, which results in incompetent, small white blood cells that compromise the immune system. CLL is one of the most common types of leukaemia in Western countries, accounting for 25% of all diagnoses.⁹ There are instances in which CLL is used as an overarching term that includes Small Lymphocytic Lymphoma (SLL) because they are both nearly the same disease, however CLL is commonly detected in the blood and bone marrow, whereas SLL is primarily detected in the lymph nodes.¹⁰

Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma is an aggressive type of blood cancer that develops in the outer part of the lymph node, an essential part of the immune system.¹¹ Affecting only 1 in 100,000 people, MCL is a very rare cancer.¹²

Multiple Myeloma (MM) and Smouldering Multiple Myeloma (SMM)

Multiple Myeloma is a rare, slow-growing cancer of the white blood cells that can damage other organs and stop healthy cells being made.¹³¹⁴ Smouldering multiple myeloma is an early precursor of active multiple myeloma.¹⁵

Waldenström's Macroglobulinaemia (WM)

Waldenström's Macroglobulinemia is a rare and slow-growing cancer of the white blood cells. It mostly grows in the bone marrow, slowing down the growth of blood cells which can lead to anaemia and a weakened immune system.¹⁶

References

[1]

Mayo Clinic. Myelodysplastic syndromes: Symptoms & causes. Available at: https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/symptoms-causes/syc-20366977. Last accessed: September 2023

[2]

Cancer.org. What Are Myelodysplastic Syndromes? Available at: https://www.cancer.org/cancer/myelodysplastic-syndrome/about/what-is-mds.html Last accessed: September 2023.

[3]

Cancer.gov. Myelodysplastic Syndromes Treatment (PDQ^®)–Patient Version. Available at: https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq Last accessed: September 2023.

[4]

MDS Foundation. What is MDS ? Available at: https://www.mds-foundation.org/what-is-mds/ Last accessed: September 2023.

[5]

Mayo Clinic. Myelodysplastic syndromes: Diagnosis. Available at: https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/diagnosis-treatment/drc-20366980 Last accessed: September 2023.

[6]

Cancer.org. What Causes Myelodysplastic Syndromes? Available at: https://www.cancer.org/cancer/myelodysplastic-syndrome/causes-risks-prevention/what-causes.html Last accessed: September 2023.

[7]

NIH National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQR) - Patient Version. Available at: https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq. Last accessed: September 2023.

[8]

Blood Cancer UK. Watch and wait. Available at: https://bloodcancer.org.uk/understanding-blood-cancer/watch-wait/ Last accessed: September 2023.